Merck to consolidate media accounts

Share this article:

Merck will consolidate media duties on all of its brands, including the newly acquired Schering-Plough portfolio, after a review.

The move, first reported by Adweek, puts the combined account – valued at approximately $600 million without digital spend, according to Nielsen figures – up for grabs, with Merck's incumbents Draftfcb and Initiative participating.

Schering-Plough incumbent Havas MPG is also in on the pitch, with final presentations planned for this March. Publicis Groupe's Zenith Media will also participate in the review, sources told Adweek. Participating agency sources verified the account review with MM&M, but couldn't offer any additional information or details, citing sensitivity on the issue. A spokesperson at Merck refused to confirm the review.

Merck alone is responsible for the bulk of the $600 million account, spending upwards of $520 million from January-November 2009. Draftfcb has previously handled planning and some buying, including digital and print. Initiative handles TV buying, according to the Adweek report.

Creative agencies that work on Merck and Schering brands, including Draftfcb, DDB Healthcare, Havas' Euro RSCG, Merkley + Partners, BBDO and TBWA\WorldHealth, are not included in the media-only review, per Adweek sources.

Interpublic Group's Initiative agency has fared well in large pharma media consolidations of late. Bayer consolidated its US media account with Initiative last November.
Share this article:

Email Newsletters

More in News

AstraZenca beefs up respiratory portfolio

AstraZenca beefs up respiratory portfolio

AstraZeneca has made an $875-million move to beef up its respiratory pipeline by making Almirall's lineup its own.

Amgen Q2 sales rise, company to lay off up to 2,900

Amgen Q2 sales rise, company to lay off ...

The majority of the layoffs will be in the US.

Doctors want to know how CMS plans to display Sunshine payment data

Doctors want to know how CMS plans to ...

Physician and industry trade groups are asking CMS to explain how context will be provided to the general public around the dollar sums drugmakers ascribe to doctors for things like ...